Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: miyamoto h. Gastric Cancer. 2017 May;20(3):527. doi: 10.1007/s10120-016-0643-z. Gastric Cancer. 2017. PMID: 27629880 No abstract available.
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: miyamoto h. Gastric Cancer. 2017 May;20(3):517-526. doi: 10.1007/s10120-016-0633-1. Epub 2016 Aug 23. Gastric Cancer. 2017. PMID: 27553665 Clinical Trial.
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. Uemura N, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2017 Oct;80(4):707-713. doi: 10.1007/s00280-017-3404-8. Epub 2017 Aug 28. Cancer Chemother Pharmacol. 2017. PMID: 28849257 Clinical Trial.
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y, Hirakawa M, Ohnuma H, Takahashi M, Okamoto T, Okamoto K, Miyamoto H, Muguruma N, Furuhata T, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2017 Dec;80(6):1133-1139. doi: 10.1007/s00280-017-3458-7. Epub 2017 Oct 16. Cancer Chemother Pharmacol. 2017. PMID: 29038850
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.
Ohnuma H, Sato Y, Hirakawa M, Kikuchi S, Miyanishi K, Sagawa T, Takahashi Y, Nobuoka T, Okamoto K, Miyamoto H, Takemasa I, Takayama T, Kato J. Ohnuma H, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2018 Mar;81(3):539-548. doi: 10.1007/s00280-018-3523-x. Epub 2018 Jan 30. Cancer Chemother Pharmacol. 2018. PMID: 29383482
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, Fujikawa K, Nobuoka T, Okamoto K, Miyamoto H, Muguruma N, Takemasa I, Takayama T. Sato Y, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2019 Jan;83(1):161-167. doi: 10.1007/s00280-018-3719-0. Epub 2018 Nov 7. Cancer Chemother Pharmacol. 2019. PMID: 30406285 Clinical Trial.
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
Nakagawa T, Sato Y, Tanahashi T, Mitsui Y, Kida Y, Fujino Y, Hirata M, Kitamura S, Miyamoto H, Okamoto K, Muguruma N, Bando Y, Takayama T. Nakagawa T, et al. Among authors: miyamoto h. Gastric Cancer. 2020 May;23(3):426-436. doi: 10.1007/s10120-019-01024-9. Epub 2019 Nov 1. Gastric Cancer. 2020. PMID: 31677131
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J. Hirakawa M, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338051 Clinical Trial.
[Prevention of colorectal cancer].
Takayama T, Miyamoto H, Muguruma N. Takayama T, et al. Among authors: miyamoto h. Nihon Shokakibyo Gakkai Zasshi. 2016 Jul;113(7):1168-75. doi: 10.11405/nisshoshi.113.1168. Nihon Shokakibyo Gakkai Zasshi. 2016. PMID: 27383099 Review. Japanese. No abstract available.
Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection.
Mitsui Y, Miyoshi A, Okamoto K, Muguruma N, Miyoshi J, Tanaka K, Kitamura S, Miyamoto H, Sato Y, Bando Y, Shunto J, Eguchi H, Okazaki Y, Ishida H, Takayama T. Mitsui Y, et al. Among authors: miyamoto h. Gastric Cancer. 2019 Nov;22(6):1294-1300. doi: 10.1007/s10120-019-01005-y. Epub 2019 Sep 16. Gastric Cancer. 2019. PMID: 31529234
1,925 results